Integration of Surgery and Systemic Therapy In the Management of Renal Cell Carcinoma By Christopher Wood, MD, FACS

This is a monthly Grand Rounds to help educate our Urology Faculty, Residents, Allied Healthcare Providers, and Community Physicians.  It is designed around Urologic topics to assist in updated medical topics and care.

Target Audience

  • Urology Faculty
  • Residents
  • Allied Healthcare Providers
  • Community Physicians

Learning Objectives

  • The participant will be able to understand the role of cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy
     
  • The participant will be able to understand the role and safety of pre-surgical therapy in the management of advanced RCC
     
  • The participant will be able to understand the proper integration of surgery and systemic therapy in the management of locally advanced RCC

 

 

Additional information

Contact

Name: 
Tammy Janik
Phone Number: 
+1 (414) 805-0788
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
09/06/2013
Course expires: 
09/20/2013
Cost:
$0.00
Activity Director
Ken Jacobsohn, MD
Assistant Professor
Department of Urology
Board Certified - American Board of Urology
No relevent financial relationships to disclose
 
Planning Committee
William See, MD
Chairman, Professor
Department of Urology
Board Certified - American Board of Urology
No relevant financial relationships to disclose
 
Christopher Wood, MD, FACS
Douglas E. Johnson, M.D. Professorship
Professor & Deputy Chairman
Department of Urology
UT MD Anderson Cancer Center
Houston, Texas
Dr. Wood has disclosed a financial relationship with Pfizer, Inc. as a consultant & Advisory Board

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$0.00
Please login or register to take this course.